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Background. Age-related macular degeneration (AMD), the leading cause of blindness in the Western world, is a complex
disease that affects people over 50 years old. The complement factor H (CFH) gene has been repeatedly shown to be a major
factor in determining susceptibility to the advanced form of the condition. We aimed to better understand the functional role
of this gene in the AMD disease process and assess whether it is associated with earlier forms of the disease. Methodology/
Principal Findings. We genotyped SNPs at the CFH gene locus in three independent populations with AMD: (a) extended
families where at least 3 family members had AMD; (b) sporadic cases of advanced AMD and (c) cases from the Age-Related Eye
Disease Study (AREDS). We investigated polymorphisms and haplotypes in and around the CFH gene to assess their role in
AMD. CFH is associated with early/intermediate and advanced AMD in both familial and sporadic cases. In our populations, the
CFH SNP, rs2274700, is most strongly associated with AMD and when incorporated into a haplotype with the Y402H SNP and
rs1061147, the strongest association is observed (p,10
29). Conclusions/Significance. Our results, reproduced in three
populations that represent the spectrum of AMD cases, provide evidence that the CFH gene is associated with drusen as well
as with advanced AMD. We also identified novel susceptibility and protective haplotypes in the AMD populations.
Citation: Francis PJ, Schultz DW, Hamon S, Ott J, Weleber RG, et al (2007) Haplotypes in the Complement Factor H (CFH) Gene: Associations with
Drusen and Advanced Age-Related Macular Degeneration. PLoS ONE 2(11): e1197. doi:10.1371/journal.pone.0001197
INTRODUCTION
Age-related macular degeneration (AMD) is the leading cause of
blindness in the developed world.[1] The hallmark of AMD is the
progressive accumulation of drusen (sub-retinal yellow deposits) at
the macula, that portion of the central retina specialized for fine
visual tasks. Evidence suggests that the risk of developing advanced
complications of the disease correlates with the amount of drusen
present in the macula. For instance, the presence of extensive large
(.125 mm in minimum diameter) drusen .393,744 mm
2 in area
represented the highest risk category for the development of
advanced AMD (19.2% in five years and 55.3% in 10 years) in the
Beaver Dam Eye Study.[2]
Advanced AMD is characterized by poor central vision following
the development of: (1) choroidal neovascularization (CNV)
associated with leakage, hemorrhage, and subretinal scarring, or
(2) geographic atrophy (GA), characterized by the appearance of
coalescing foci of retinal pigment epithelial atrophy.[1] AMD is
a complex disease since its development is determined by the effects
and interactions of a number of genes and environmental risk
factors. In the last few years, considerable advances have been made
in identifying AMD susceptibility genes, in particular those
implicated in the development of advanced disease. The association
of single nucleotide polymorphisms (SNPs) in the CFH (Y402H,
C1277T, rs1061170)[3–7] and LOC387715 (A69S, rs10490924)[8–
11] and HTRA1 genes[12] with advanced AMD susceptibility have
now been replicated in a number of independent studies.
Furthermore, there is now evidence that specific SNP haplotypes
within the chromosomal loci of these genes confer increased risk of
CNV development or appear relatively protective.[13,14]
Other genes have been implicated in AMD development,
including complement component 2 (CF2) and factor B (BF),[15]
toll-like receptor 4 (TLR4),[16] and potentially a sequence variant in
hemicentin-1 (HMCN-1)[17,18] which resides close to the CFH
locus on 1q. However, the precise role of these genes and others[11]
in determining susceptibility to the condition remains to be fully
evaluated. The role of these genes in earlier AMD phenotypes is not
yet established.
In this article, we present the results of analyses of 3 populations
with AMD: extended families genetically enriched for their
predisposition to the disease, sporadic cases of advanced AMD,
and the Age-Related Eye Disease Study (AREDS) cohort. We
investigated associations with polymorphisms and haplotypes in
the CFH gene. Furthermore, since our cohorts included
individuals with earlier stages of AMD, the potential role of
CFH in drusen formation was explored.
RESULTS
Association of individual SNPs in and around CFH
with advanced AMD
The CFH risk allele rs1061170 ‘C’ and AMD was strongly
associated with advanced AMD status in each of the three cohorts:
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PLoS ONE | www.plosone.org 1 November 2007 | Issue 11 | e1197(1) a cohort of families with AMD (1253 Caucasian affected and
unaffected individuals from 124 extended families (average age
68.2 years; 492 males, 761 females); (2) a sporadic case/control
cohort:211sporadiccases(age79 years,range57–100;70male,141
female;210 Caucasian,1 Otherracial origin)ofadvanced AMD and
183 unrelated ophthalmologically evaluated controls (age 74, range
63–92; 81 male, 102 female; 183 Caucasian; 2201 cases and controls
from the Age-related Eye Disease Study (AREDS).
Associations with several other SNPs in the CFH gene and
advanced AMD status were also surveyed in these populations and
significant associations were also noted for SNPs rs529825,
rs800292, rs1061147, rs203674 and rs2274700 (table 1). The
SNP most strongly associated with advanced AMD was the
synonymous exon 10 SNP, rs2274700.
Susceptibility and protective haplotypes at the CFH
locus
A subtractive approach utilized 27 haplotypes to determine the
combination of SNPs with the lowest p-value of association with
AMD using FBAT. This best combination comprised the
following 3 SNPs: rs1061147, rs1061170, rs2274700 (p,0.0002,
Table 2). Two nucleotide combinations of this 3-SNP haplotype
were significantly associated with AMD status: rs1061147 ‘A’,
rs1061170 ‘C’, rs2274700 ‘C’ and rs1061147 ‘C’, rs1061170 ‘T’,
rs2274700 ‘T’. The other rs1061147, rs1061170, rs2274700
haplotype ‘C T C’ was not associated with AMD.
We then investigated whether these haplotypes were associated
with AMD development in the AREDS and case-control popula-
tions and found similar results (Table 3). Since the ‘CTC’ haplotype
conferred no additional odds of developing AMD, it was also
possible in the populations to assess the direction of the effects,
finding that the ACC haplotype conferred higher disease odds and
the CTT haplotypeconferredlowerdiseaseodds of advanced AMD.
In our 3 populations, we found that neither individual SNPs nor
the 3-SNP haplotype was preferentially associated with either the
neovascular or geographic atrophy form of advanced AMD.
Association of CFH (Y402H) with early and
intermediate AMD
Table 4 shows the prevalence of rs1061170 (Y402H) for each
category of AMD from category 1 (no AMD), through increasing
stages of drusen (categories 2 and 3) to advanced AMD (category
4) in both the AREDS and familial AMD cohorts.
The highest prevalence of this risk allele is in advanced AMD
(category 4) and lowest in the unaffected controls (category 1, no
AMD), as illustrated in Table 4. The prevalence of the risk allele
increases in those with mild drusen (category 2, early AMD) and
increases further in eyes with large drusen (category 3, in-
termediate AMD).
DISCUSSION
In this study, we confirm the strong association between
polymorphisms in the complement factor H gene and advanced
age-related macular degeneration in 3 independent predominantly
Caucasian populations. For the first time, we report this
association in families in whom there is increased susceptibility
among relatives to develop the condition. The prevalence of the
risk allele ‘C’ for the coding SNP rs1061170 (Y402H) present in
exon 9 of the gene in cases of advanced AMD is broadly
comparable to that previously reported in sporadic case-control
Table 1. Single SNP analysis.
..................................................................................................................................................
SNP Location and change Sample OR (lower bound–upper bound) P-value Fbat p value
rs529825 IVS1 Family Data 0.013
Case Control 2.67 (2.22–3.12) ,0.0001
AREDS 2.57 (1.81–3.33) 0.018
rs800292 Exon 2, I62V Family Data 0.002
Case Control 2.35 (1.95–2.75) ,0.0001
AREDS 2.52 (1.75–3.28) 0.022
rs3766404 IVS6 Family Data 0.096
Case Control 3.82 (3.292–4.354) ,0.0001
AREDS 3.77 (2.59–4.95) 0.030
rs1061147 Exon 7, A307A Family Data 0.004
Case Control 2.53 (2.21–2.85) ,0.0001
AREDS 2.05 (1.54–2.56) 0.008
rs1061170 Exon 9, Y402H Family Data 4.36 (3.51–5.21){ 0.006
Case Control 2.40 (2.07–2.73) ,0.0001
AREDS 2.04 (1.54–2.54) 0.007
rs203674 IVS10 Family Data 0.02
Case Control 2.68 (2.34–3.02) ,0.0001
AREDS 2.13 (1.61–2.65) 0.006
rs2274700 Exon 10, A473A Family Data 0.0002
Case Control 3.07 (2.74–3.41) ,0.0001
AREDS 3.32 (2.67–3.97) 0.0003
Emboldened numbers indicate statistically significant p-values allowing for multiple testing. Number in italics indicated most significant p-value. For IVS1 and I62V
confer decreased odds of developing AMD.
doi:10.1371/journal.pone.0001197.t001
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
Haplotype and Risk of AMD
PLoS ONE | www.plosone.org 2 November 2007 | Issue 11 | e1197populations[3,4] and in the other 2 cohorts evaluated in this
study.[12] Similarly, the odds ratio of having advanced AMD,
based on the number of ‘C’ alleles present, was also comparable to
previous studies.
We chose the 7 SNPs to be genotyped based upon those
previously shown to be associated with AMD at the CFH gene
locus: rs529825, rs3766404, rs1061147, rs800292, rs1061170,
rs203674 and rs2274700.[4] A backward step-wise selection
method and the FBAT were chosen because multi-SNP effects
are allowed that are not additive. If a forward selection method is
used, those SNPs that have the largest additive effect are most
likely to be in the model. If 2 SNPs have a non-additive effect but
no large marginal effects, it would be impossible to detect them
using forward selection. If 2 SNPs only have an effect
Table 2. Haplotypes and their association with AMD in the familial AMD cohort.
..................................................................................................................................................
Number of SNPs SNPs involved in best model Haplotypes Frequency
Haplotype
p-values
Overall
p-value
7 rs3766404 rs529825 rs1061147 rs800292 rs1061170 rs203674 rs2274700 TCACCCC 0.58 0.03
TCCCTAC 0.12 0.90
TTCTTAT 0.11 0.10 0.12
6 rs3766404 rs529825 rs1061147 rs800292 rs1061170 rs2274700 TCACC C 0.56 0.02
TCCCT C 0.18 0.44
TTCTT T 0.11 0.13
CCCCT T 0.06 0.09 0.02
5 rs529825 rs1061147 rs800292 rs1061170 rs2274700 CACC C 0.55 0.01
CCCT C 0.18 0.31
TCTT T 0.11 0.18
CCCT T 0.10 0.02 0.006
4 rs1061147 rs800292 rs1061170 rs2274700 ACC C 0.56 0.00
CCT C 0.18 0.31
CTT T 0.12 0.07
CCT T 0.100 0.03 0.0008
3 rs1061147 rs1061170 rs2274700 A C C 0.56 0.0006
C T T 0.25 0.0003
C T C 0.17 0.35 0.00008
2 rs1061147 rs1061170 A C 0.56 0.00008
C T 0.41 0.004 0.0001
1 rs1061170 C 0.58 0.006
T 0.42 0.006 0.006
The most strongly associated haplotype (shown in red) is derived from SNPs genotyped in the CFH gene locus using backward selection. Emboldened ‘C’ indicates CFH
rs1061170 risk allele. ‘Best’ haplotype shown in italics. Overall p value describes association of the haplotype with AMD independent of alleles
doi:10.1371/journal.pone.0001197.t002
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
Table 3. Replication of best haplotype in (a) case control data and (b) AREDS data.
..................................................................................................................................................
Case control cohort
Haplotype Hap Score
Pooled Haplotype
Frequency
Control Haplotype
Frequency
Case Haplotype
Frequency
OR (lower bound–upper
bound)
Associated
P-value
Overall
p value
ACC 25.85 0.47 0.36 0.57 0.43 (0.29–0.64) ,10
29 ,0.00001
CTT 27.83 0.33 0.48 0.20 3.88 (2.51–6.01) ,10
214
CTC 21.07 0.20 0.16 0.23 0.62 (0.38–1.03) 0.28
AREDS cohort
Haplotype Hap Score
Pooled Haplotype
Frequency
Control Haplotype
Frequency
Case Haplotype
Frequency
OR (lower bound–upper
bound)
Associated
P-value
Overall
p value
ACC 24.28 0.44 0.35 0.58 0.40 (0.30–0.52) ,0.0001 ,0.00001
CTT 24.79 0.36 0.46 0.21 3.08 (2.30–4.13) ,0.0001
CTC 20.30 0.20 0.19 0.21 0.90 (0.64–1.27) 0.77
The odds ratios are computed by comparing each haplotype against all other haplotypes pooled. Cases defined as AREDS category 4, advanced AMD. Controls defined
as AREDS category 1, unaffected. Overall p value describes association of the haplotype with AMD independent of alleles
doi:10.1371/journal.pone.0001197.t003
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PLoS ONE | www.plosone.org 3 November 2007 | Issue 11 | e1197simultaneously, using this model misses them. Only if a SNP has
a combined influence with SNPs that already have a large effect
will it be detected by forward selection. Using backward step-wise
selection, we identified a 3-SNP haplotype comprising rs1061147
‘A’, rs1061170 ‘C’, rs2274700 ‘C’ as the most strongly associated
with AMD in our familial AMD cohort. Analyses performed in
our other 2 populations comprising sporadic cases and controls
and the AREDS cohorts confirmed this association.
There are considerable similarities between the findings in our
study of CFH haplotypes and the other three studies previously
published on the subject. Hageman and colleagues[4] sequenced
all 22 coding exons of the CFH gene and their 50- to 100-bp
flanking intronic sequences in the University of Iowa cohort,
finding a total of 26 sequence variants: 17 SNPs in the coding
region, including 5 synonymous and 12 non-synonymous
substitutions and 9 intronic SNPs. They found several highly
significant associations with AMD, including the non-synonymous
I62V, Y402H and the IVS2 variants. The strongest association
with AMD in this cohort was observed with the synonymous
A473A (rs2274700) variant in exon 10. In our study of 3
independent populations, we similarly find these associations and
show that their most significantly associated variants form 2 of the
3 SNPs in our haplotype. In addition, when the non-disease
associated alleles are inherited in this haplotype, they appear
protective for the presence of AMD.
Li[14] examined 84 polymorphisms in and around CFH in 726
affected individuals in a case-control cohort, finding 20 poly-
morphisms that showed stronger association with disease suscep-
tibility than the Y402H variant. These investigators defined a set
of 4 common haplotypes (of which 2 were associated with disease
susceptibility and 2 appeared protective). Their strongest associ-
ated SNP was the synonymous variant rs2274700 (A473A), which
is one of the SNPs in our haplotypes that confer increased or
decreased risk of AMD.
Maller and coworkers[13] performed a case-control study
drawn from a US-based population of European descent,
identifying a previously unrecognized common, non-coding
variant in CFH (rs1410996) that was associated with advanced
AMD as well as the previously recognized Y402H change. Using
stepwise logistic regression, even after conditioning for each of the
SNPs, the authors found that both remained strongly associated
with disease. In our study, we did not genotype for the rs1410996
SNP. However, our 3-SNP disease-associated haplotype does
comprise the Y402H sequence change.
In summary, our 3-SNP haplotype is a good ‘fit’ for those
previously described. Furthermore, we have been able to confirm
its validity in 3 independent well-phenotyped populations. In-
terestingly, apart from the CFH Y402H SNP, the other two are
synonymous coding variants, suggesting that these sequence
changes do not combine to effect some reduction in protein
function but more likely alter expression levels of the CFH gene
and possibly other complement factor-related genes[14].
It is now established that the Y402H CFH change is associated
with advanced AMD. Whether this polymorphism also contributes
to other earlier AMD phenotypes remains to be fully explored.
Only one other report has addressed this issue finding increased
frequency of the risk allele in individuals with drusen[19]. Because
two of our cohorts (AREDS and familial AMD) comprised
individuals with intermediate stages of AMD, ie varying degrees of
drusen, in comparable categories, we were able to address this
question. There was a statistically significant association with
increasing amounts of drusen in both of these cohorts suggesting
a role for CFH in these earlier stages of AMD. Such an association
is biologically plausible since complement factors, including CFH
have been identified in drusen.[20]
We found that the frequency of the risk allele was similar among
those with advanced AMD in all three groups (approximately
0.60). Interestingly, this same allele frequency is observed in those
individuals with intermediate AMD (drusen) with a strong family
history of AMD and higher than in those with the same category
of AMD in the AREDS cohort. Our future longitudinal studies
will evaluate whether this is because individuals with a family
history of AMD, who have both extensive drusen and the CFH
risk allele are at very high risk of progression to choroidal
neovascularization and/or geographic atrophy.
Previous studies have failed to show that CFH associates more
frequently with the presence of either CNV or GA. In our 3
populations, we also found that neither the SNPs in and around
the CFH gene nor the 3-SNP haplotype preferentially increased
susceptibility to one of these late complications.
In summary, we have examined 3 independent, carefully
phenotyped populations with AMD. These populations can be
considered to reflect the full diversity of AMD patients: those with
familial susceptibility to the condition and 2 case-control popula-
tions, one of which was followed for more than 10 years as part of
a nationwide clinical trial. We have confirmed the association
between the Y402H CFH mutation and advanced AMD finding
however the strongest association with another SNP within the gene,
rs2274700 in agreement with two other studies[13,14]. In addition,
we have found that these two SNPs, when partofa 3-SNPhaplotype
confer considerably increased odds of AMD development compared
withtheSNPsassessedsingly.OurdataalsomakesacaseforCFHto
have a role in drusen formation and progression as well as the
development of late complications, such as choroidal neovascular-
ization or geographic atrophy.
MATERIALS AND METHODS
All studies involving human subjects were approved by the
Institutional Review Board of Oregon Health & Science
Table 4. Frequency of the rs1061170 CFH Y402H risk allele ‘C’ by category of AMD.
..................................................................................................................................................
AMD category AREDS cohort Familial AMD cohort Case control cohort
Number of
individuals
‘C’ allele
frequency P value
Number of
individuals
‘C’ allele
frequency P value
Number of
individuals
‘C’ allele
frequency P value
1 306 0.36 97 0.47 211 0.36
2 502 0.38 0.46 55 0.49 0.84
3 526 0.48 ,10
25 95 0.63 0.002
4 578 0.61 ,10
222 124 0.63 0.001 183 0.59 ,10
210
P-values calculated for allelic test of association for differences in AMD grade (categories 2, 3 and 4) from category 1 (no AMD)
doi:10.1371/journal.pone.0001197.t004
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PLoS ONE | www.plosone.org 4 November 2007 | Issue 11 | e1197University. Research followed the tenets of the Declaration of
Helsinki, and written informed consent was obtained from all
subjects after explanation of the nature and possible consequences
of the study.
Study populations and phenotyping
AMD family cohort Each family comprised at least three
examined (and genotyped) affected relatives with AMD.
Individuals were identified as follows: category 1, (no AMD) no
drusen or drusen less than 63 mm diameter, and no pigment
changes in either eye; category 2, mild to moderate drusen
consisting of drusen of any size, but ,393,744 mm
2 in total area
within 1500 mm from the fovea, with or without pigment changes;
category 3, extensive large drusen (.125 mm in minimum
diameter) .393,744 mm
2 in area (a minimum of approximately
20 large drusen) within 1500 mm of the fovea, with or without
pigment changes and no evidence of advanced AMD; category 4
(advanced AMD), presence in one or both eyes of advanced
macular degeneration (choroidal neovascularization or geographic
atrophy)[21,22]. For the purposes of cross-comparison between
cohorts, these categories are similar to AREDS categories 1–4.
Categories 2 and 3 are equivalent to AREDS category 3, with
category 3 eyes considered an extremely high risk group for
progression to advanced AMD (geographic atrophy or choroidal
neovascularization).
Sporadic cases and controls were ascertained from our clinical
practice. Diagnosis of AMD in cases was based upon the presence
of geographic atrophy or choroidal neovascularization (equivalent
to AREDS category 4, see below).[23] Control subjects were at
least 60 years of age, with no signs of AMD defined as no drusen
larger than 63 microns in diameter.
AREDS cohort The Age-Related Eye Disease Study was an
eleven-center double-masked clinical trial investigating the effects
of oral antioxidant and vitamin supplements on disease
progression. DNA was extracted from venous blood from 2201
individuals (939 males, 1262 females; 2115 Caucasian, 72 African
American, 6 Hispanic, 3 Asian, 5 Other racial origin) which
comprised approximately one-half the AREDS participants
(obtained from the AREDS Genetic Repository). Participants
were aged 67.7 years (range 55–80) years. The AREDS study
procedures have been previously reported.[24,25] Briefly,
participants were classified into 5 groups: category 1 (343
individuals), no AMD; category 2 (578 individuals), extensive
small drusen or intermediate drusen; category 3 (624 individuals),
large drusen, non-central geographic atrophy or pigment
abnormalities in 1 or both eyes; category 4 (285 individuals),
advanced AMD (CNV or GA) or vision loss due to AMD in one
eye. At least one eye had best-corrected visual acuity of 20/32 or
better21; category 5 (368 individuals), advanced AMD in both
eyes. All patients were included in this study irrespective of their
treatment assignment.
Genotyping
Seven SNPs in and around the CFH gene locus were chosen:
rs3766404, rs529825, rs1061147, rs800292, rs1061170, rs203674
and rs2274700. Genotyping was performed using Sanger
sequencing at Prevention Genetics (3700 Downwind Drive,
Marshfield, Wisconsin, USA) and at the Broad Institute Center
for Genotyping and Analysis, Cambridge, MA, USA.
Statistical analyses
Association analyses To estimate SNP frequencies and
determine if the frequencies differed between affected and
unaffected individuals in the pedigrees, the Family Based
Association Test (FBAT) was used.[26] Adjusted unconditional
logistic regression was used to determine the relationship between
the CFH rs1061170 genotype and other CFH SNPs and AMD
status in the other 2 populations. Additionally, a test for trend
related to the number of risk alleles (0, 1, 2) was calculated.
Haplotype analyses FBAT was used to estimate haplotype
frequencies and any that occurred less than 10 times in combined
cases and controls were eliminated from the analysis. Since 7 SNPs
were measured in this gene, all 7 SNPs (see above genotyping)
were used to produce the first haplotype model. Then 1 SNP was
removed at a time to create 7 models, each containing 6 SNPs. Of
these 7 models, the one with the lowest associated p-value was
deemed the best model. Then 1 SNP was removed at a time from
this best 6-SNP model to create 6 models, each containing 5 SNPs.
The 5-SNP model with the lowest associated p-value was then the
best 5-SNP model. This process was continued to find the best 4-
SNP, 3-SNP, 2-SNP and 1-SNP models. Overall, we performed
27 tests. All 27 models were evaluated to determine which had the
lowest associated p-value. The Bonferroni was used to adjust for
multiple testing.
The SNPs from the model with the lowest associated p-value
were used to determine if one haplotype effect replicated in 2
additional samples. We used haplo.stat (a program in R) to
estimate haplotype frequencies, determine if these differed
between cases and controls, determine if individual haplotypes
differed significantly between cases and controls and estimate an
odds ratio for each individual haplotype.[27] Any of the
haplotypes that occurred less than 10 times in combined cases
and controls were eliminated from the analysis.
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